Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9‐39) for treatment of post‐bariatric hypoglycaemia
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the safety, efficacy and pharmacokinetics of repeat dosing of two formulations of subcutaneous (SC) avexitide (exendin 9‐39) in patients with post‐bariatric hypoglycaemia (PBH). Methods: In this phase 2, multiple‐ascending‐dose study conducted at Stanford University, 19 women with PBH underwent a baseline oral glucose tolerance test (OGTT), with metabolic and symptomatic assessments. Fourteen were then sequentially assigned to receive one of four ascending‐dose levels of twice‐daily lyophilized (Lyo) avexitide by SC injection for 3 days. On the basis of safety, efficacy and tolerability, five additional participants then received a novel liquid formulation (Liq) of avexitide by SC injection at a fixed dose of 30 mg twice daily for 3 days. All 19 participants underwent a repeat OGTT on day 3 of dosing to quantify metabolic, symptomatic and pharmacokinetic responses. Results: Treatment with Lyo avexitide reduced the magnitude of symptomatic hyperinsulinaemic hypoglycaemia at all dose levels, with dose‐dependent improvements in glucose nadir, insulin peak and symptom score; doses ≥20 mg twice daily did not require glycaemic rescue (administered at glucose <2.8 mmol/L). Participants receiving Liq avexitide 30 mg twice daily did not require any glycaemic rescue, and on average achieved a 47% increase in glucose nadir, a 67% reduction in peak insulin, and a 47% reduction in overall symptom score. Equivalent doses of Liq versus Lyo avexitide yielded higher and more sustained plasma concentrations. Both formulations were well tolerated. Conclusions: In patients with PBH, twice‐daily administration of SC avexitide effectively raised the glucose nadir and prevented severe hypoglycaemia requiring rescue intervention. Avexitide may represent a viable therapy for PBH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
Ward, Z. J., Bleich, S. N., Cradock, A. L., Barrett, J. L., Giles, C. M., Flax, C., Long, M. W., & Gortmaker, S. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmsa1909301 · Cited by 2,009
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Goldfine, A. B., Mun, E. C., Devine, E., Bernier, R., Baz-Hecht, M., Jones, D. B., Schneider, B. E., Holst, J. J., & Patti, M. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0918 · Cited by 377
Patti, M. E., McMahon, G., Mun, E. C., Bitton, A., Holst, J. J., Goldsmith, J., Hanto, D. W., Callery, M., Arky, R., Nose, V., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1933-x · Cited by 365
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“Avexitide (chemical name: exendin 9-39) is a first-in-class competitive GLP-1 receptor antagonist.(32,33) Avexitide is the chemically synthesized N-terminus 31-amino-acid fragment of exendin-4, a 39amino-acid naturally occurring peptide isolated from the saliva of the Gila monster, Heloderma suspectum,(34,35) which ha…”
BackgroundBlockade of Glucagon-like Peptide 1 Receptor Corrects Postprandial Hypoglycemia After Gastric Bypass
Salehi, M., Gastaldelli, A., & D'Alessio, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.044 · Cited by 289 · cited 2×
“Symptoms were assessed by the study coordinator prior to the OGTT and every 30 minutes after using the Edinburgh Hypoglycaemia Symptom Scale (EHSS)(37) as previously described.(30,31,36) Metabolic and symptomatic assessments during the OGTT are shown in Figure 1.”
BackgroundMethodPartitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis
Deary, I. J., Hepburn, D. A., MacLeod, K. M., & Frier, B. M. (1993) · Diabetologia · doi:10.1007/bf00401150 · Cited by 286
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
McLaughlin, T., Peck, M., Holst, J., & Deacon, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1628 · Cited by 183
Self-citationLee, C. J., Clark, J. M., Schweitzer, M., Magnuson, T., Steele, K., Koerner, O., & Brown, T. T. (2015) · Obesity · doi:10.1002/oby.21042 · Cited by 159 · cited 1×
“6% of cases severe enough to cause seizure or syncope, or require third-party assistance or treatment at a medical facility.(2) Affected patients typically have multiple hypoglycaemic episodes per day, with frequency of severe episodes characterized by neuroglycopenic symptoms ranging from daily to several times per m…”
BackgroundClancy, T. E., Moore, F. D., & Zinner, M. J. (2006) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2006.04.008 · Cited by 133
Campos, G. M., Ziemelis, M., Paparodis, R., Ahmed, M., & Belt Davis, D. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2013.05.012 · Cited by 104
Abrahamsson, N., Engström, B. E., Sundbom, M., & Karlsson, F. A. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0504 · Cited by 99 · cited 1×
“When medical nutrition therapy is insufficient to prevent hypoglycaemia, off-label use of various pharmacotherapies is often attempted, with variable efficacy described in case reports and case series including acarbose,(11,12) diazoxide,(13,14) somatostatin analogues(15) calcium channel blockers,(16) and glucagon-lik…”
BackgroundMedical Nutrition Therapy for Post-Bariatric Hypoglycemia: Practical Insights
Suhl, E., Anderson-Haynes, S.-E., Mulla, C., & Patti, M.-E. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.01.025 · Cited by 96 · cited 1×
“Conservative management starts with medical nutrition therapy, consisting of small frequent mixed meals that combine protein and fat with a small amount of carbohydrate (15–30 g per meal).(10) When medical nutrition therapy is insufficient to prevent hypoglycaemia, off-label use of various pharmacotherapies is often a…”
BackgroundMyint, K. S., Greenfield, J. R., Farooqi, I. S., Henning, E., Holst, J. J., & Finer, N. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1065 · Cited by 77
Lee, C. J., Brown, T. T., Schweitzer, M., Magnuson, T., & Clark, J. M. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.01.028 · Cited by 49
Successful Treatment of Persistent Hyperinsulinemic Hypoglycemia with Nifedipine in an Adult Patient
Guseva, N., Phillips, D., & Mordes, J. P. (2010) · Endocrine Practice · doi:10.4158/ep09110.crr · Cited by 35
Craig, C. M., Lamendola, C., Holst, J. J., Deacon, C. F., & McLaughlin, T. L. (2015) · AACE Clinical Case Reports · doi:10.4158/ep14218.cr · Cited by 15
Self-citation
Cited by
Metabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Craig, C. M., Lawler, H. M., Lee, C. J. E., Tan, M., Davis, D. B., Tong, J., Glodowski, M., Rogowitz, E., Karaman, R., McLaughlin, T. L., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab103 · Cited by 69
Self-citationDo Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
Papamargaritis, D., & le Roux, C. W. (2021) · Nutrients · doi:10.3390/nu13030762 · Cited by 68
Llewellyn, D. C., Logan Ellis, H., Aylwin, S. J. B., Oštarijaš, E., Green, S., Sheridan, W., Chew, N. W. S., le Roux, C. W., Miras, A. D., Patel, A. G., et al. (2023) · Obesity · doi:10.1002/oby.23600 · Cited by 54
Sheehan, A., & Patti, M. E. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s233078 · Cited by 39
Metadata
- Authors
- Tan, M., Lamendola, C., Luong, R., McLaughlin, T., & Craig, C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-05-04
- Volume
- 22
- Issue
- 8
- Pages
- 1406-1416
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3014464491
- Cited by
- 36
- References
- 19
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.